.Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AE24_Tavaborole.Tavaborole .Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AE24_Tavaborole.Tavaborole| name: | Tavaborole |
| ATC code: | D01AE24 | route: | topical |
| n-compartments | 1 |
Tavaborole is a topical antifungal agent used to treat onychomycosis (fungal infection of the toenails or fingernails) in adults. It acts by inhibiting leucyl-tRNA synthetase, thereby disrupting protein synthesis in fungal cells. It is an FDA-approved treatment for onychomycosis of the toenails caused by Trichophyton rubrum or Trichophyton mentagrophytes.
Pharmacokinetic parameters estimated in healthy adults based on available FDA label and review information. No published studies report quantitative compartmental pharmacokinetic models for tavaborole in humans.
Gregoriou, S, et al., & Rigopoulos, D (2022). Novel and Investigational Treatments for Onychomycosis. Journal of fungi (Basel, Switzerland) 8(10) –. DOI:10.3390/jof8101079 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36294644
Rich, P, et al., & Crook, TJ (2019). Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study. Journal of drugs in dermatology : JDD 18(2) 190–195. PUBMED:https://pubmed.ncbi.nlm.nih.gov/30811142
Gupta, AK, & Studholme, C (2016). Novel investigational therapies for onychomycosis: an update. Expert opinion on investigational drugs 25(3) 297–305. DOI:10.1517/13543784.2016.1142529 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26765142